CLL Information & Management Archives

November 21, 2023

Resistance Mutations in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

Mutations at BTK C481 are the most common mutations seen in pooled trial data of chronic lymphocytic leukemia (CLL) patients on ibrutinib, leading to resistance and progressive disease (PD).

November 14, 2023

MRI Imaging Shows Changes to Heart Muscle in Some Patients on Ibrutinib for CLL and Other Blood Cancers

A newly published paper in JAMA Oncology found that among cancer patients with suspected ibrutinib-related cardiotoxic effects, the presence of heart muscle injury and scarring is high, and this is associated with an increased risk of developing future cardiovascular adverse events.

November 14, 2023

Life Expectancy Improves When CLL Is Treated with Target Therapies

The study looked at 5-year overall survival (OS) in treatment naïve CLL (chronic lymphocytic leukemia) patients who were unfit or > 65 years old compared to an age and gender-matched general population (AGMGP) without CLL.

November 14, 2023

Epcoritamab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Epcoritamab, a novel subcutaneous (an under-the-skin injection) CD3xCD20 bispecific antibody, resulted in a 62% response rate in high-risk, difficult-to-treat relapsed or refractory (R/R) CLL patients that so far appears to be durable.

November 14, 2023

Is It Safe to Stop Ibrutinib Therapy for CLL After Multiple Years?

For most CLL (chronic lymphocytic leukemia) patients who have received six years of continuous ibrutinib treatment, the levels of residual disease decrease or remain stable for the subsequent 6-12 months after stopping ibrutinib.

November 14, 2023

Can Surrogate Markers Speed Up Clinical Trials in CLL?

Both progression free survival (PFS) and measurable (minimal) residual disease (MRD) status were found to strongly correlate with overall survival (OS), suggesting these markers could be safely used as surrogates for OS and thus provide quicker results in clinical trials.

November 14, 2023

Biology and Genetics of Richter’s Transformation

This was a very complex basic science presentation from iwCLL 2023 by Erin Parry, MD. Ph.D. of Dana Farber Cancer Institute in Boston, MA on the evolution of CLL (chronic lymphocytic leukemia) to Richter’s transformation (RT),

November 14, 2023

Glofitamab for Richter’s Transformation Gives Durable Remission

Fixed-duration glofitamab, a bispecific T-cell engager (BITE) monoclonal antibody, induces durable complete remissions (CR) and has a manageable safety profile in patients with Richter’s transformation.

October 31, 2023

Venetoclax Combined with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Five years after completing venetoclax – obinutuzumab to treat chronic lymphocytic leukemia (CLL), over half of the treatment-naive patients remained in remission, and over 60% did not require second-line treatment, including many high-risk patients.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

CLL Information & Management

Resistance Mutations in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib

MRI Imaging Shows Changes to Heart Muscle in Some Patients on Ibrutinib for CLL and Other Blood Cancers

Life Expectancy Improves When CLL Is Treated with Target Therapies

Epcoritamab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Is It Safe to Stop Ibrutinib Therapy for CLL After Multiple Years?

Can Surrogate Markers Speed Up Clinical Trials in CLL?

Biology and Genetics of Richter’s Transformation

Glofitamab for Richter’s Transformation Gives Durable Remission

Venetoclax Combined with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT